Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03592121
Other study ID # RJ-101-RCT-001
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date July 9, 2018
Est. completion date October 12, 2019

Study information

Verified date February 2020
Source Applied Biology, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to investigate the possibility that a topical drug could restore nipple sensitivity and improve sexual quality of life in breast cancer survivors.


Description:

Approximately, 80% of breast cancer survivors undergoing will suffer from a permanent reduced reduction in nipple sensitivity and associated lowerdecrease in sexual quality of life. Currently, there are no treatments for restoring nipple sensitivity and the associatedto improve lower sexual quality of life this condition. It would thus be of great clinical benefit to post breast surgery patients if a provide a new safe and , effective , topical , on-demand, treatment for this condition can be developed.


Recruitment information / eligibility

Status Completed
Enrollment 3
Est. completion date October 12, 2019
Est. primary completion date October 12, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Female breast cancer survivor

- Age: 18 to 70

- First diagnosed with Stage I or II breast cancer

- Have had breast surgery: nipple sparring mastectomy or lumpectomy

- At least 3 years post surgery

- Nipple neuropathy post breast surgery (change in Llikeart scale >= 3 between pre and post surgery)

- Baseline nipple sensitivity <=5 (likeartLikert scale)

- QoL-BC (>=7)

- Delayed orgasm (CTCAE v4.0) Grade 2

- One of the following: Delayed orgasm (CTCAE v4.0) Grade 2 and/or Vaginal dryness (CTCAE v4.0) Grade 2 or 3

- Able to give informed consent

- Currently in a monogamous heterosexual relationship for at least 12 months

- Sexually active within the last 30 days

- Willing to engage in sexual activity at least once a month during the duration of the study

- Willing to use on a regular basis a web based form system to record sexual events i.e., have access to the Internet

- Willing to use an adequate method of birth control

- Able to comply with the study requirements for 8 consecutive weeks

- Able to give informed consent

Exclusion Criteria:

- Previous adverse event to alpha 1 agonists (oral, nasal, topical, or ocular) or drugs in this class

- Currently pregnant

- Nursing within the last 6 months prior to beginning the study

- History of cardiovascular or cerebrovascular disease, e.g., heart attack, disease of the arteries of the heart, partial heart block, rapid ventricular heartbeat, slow heartbeat, chronic heart failure, severe hardening of the arteries, blood clot in an artery

- Actively being treated for breast cancer

- Changes in chronic medication for oncology, cardiology, or endocrinology in past 12 months

- Uncontrolled or severe hypertension

- Decreased oxygen in the tissues or blood

- Active inflammation of the liver

- Acute inflammation of the pancreas

- Overactive thyroid gland

- Acidosis

- Diabetes

- Spinal cord injury

- Nipple dermatitis

- Regional complex pain syndrome

- Use of any hypertensive drugs

- Use of MAO inhibitors

- Subjects assigned to interventional drug arm and failed to report an increase >=2 from baseline in nipple sensitivity (likert scale) during phase I

- In partners: sexual dysfunction or erectile dysfunction

- Currently enrolled in any other medical study or has been enrolled in any medical study in the past 30 days

- Nipple dermatitis

- Regional complex pain syndrome

- Unable to provide consent or make allotted clinical visits

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AB-101
Apply approximately 1 hour prior to sexual activity
Placebo
Apply approximately 1 hour prior to sexual activity

Locations

Country Name City State
United States Southern CA Center for Sexual Health and Survivorship Medicine Newport Beach California

Sponsors (1)

Lead Sponsor Collaborator
Applied Biology, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Delayed Orgasm Grade Change in Delayed Orgasm Grade (CTCAE v4.0 - Common Terminology of Adverse Events) CTCAE v4.0 is the NIH Common Terminology of Adverse Events v4.0
Delayed Orgasm is defined as: A disorder characterized by sexual dysfunction characterized by a delay in climax.
This is a binary grading system:
Grade 0:Delay in achieving orgasm not adversely affecting relationship Grade 1:Delay in achieving orgasm adversely affecting relationship
[baseline, week 8]
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A